New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

November 13, 2023Ryan ScottNicholas C. Rohs, MDCase studies in lung cancer allow for clinicians to gather feedback and discuss the nuances of different situations, according to Nicholas C. Rohs, MD. D
World medicine November 16,2023
Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

November 13, 2023Ryan ScottNicholas C. Rohs, MDCase studies in lung cancer allow for clinicians to gather feedback and discuss the nuances of different situations, according to Nicholas C. Rohs, MD. D
World medicine November 16,2023
Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

June 12, 2022Kristi RosaThe combination of pelabresib and ruxolitinib produced responses that proved to be durable beyond week 24 in patients with myelofibrosis who experienced a suboptimal response t
World medicine November 16,2023
Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

Pelabresib/Ruxolitinib Combo Demonstrates Promising Clinical Efficacy in Myelofibrosis

June 12, 2022Kristi RosaThe combination of pelabresib and ruxolitinib produced responses that proved to be durable beyond week 24 in patients with myelofibrosis who experienced a suboptimal response t
World medicine November 16,2023
Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

February 17, 2023Kristi RosaOrca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encou
World medicine November 16,2023
Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

February 17, 2023Kristi RosaOrca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encou
World medicine November 16,2023
Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

May 4, 2021Kristi RosaThe addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow trans
World medicine November 16,2023
Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

Motixafortide/G-CSF Results in 4.9-Fold Increase in Achieving Target Stem-Cell Mobilization for Transplant in Myeloma

May 4, 2021Kristi RosaThe addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow trans
World medicine November 16,2023
KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

September 9, 2021Jamie CesanekThe effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.Carfilzomib-lenalidomide-dexam
World medicine November 16,2023
KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

September 9, 2021Jamie CesanekThe effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.Carfilzomib-lenalidomide-dexam
World medicine November 16,2023
KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25, 2023Caroline SeymourMaintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients wi
World medicine November 16,2023
KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25, 2023Caroline SeymourMaintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients wi
World medicine November 16,2023
FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

November 15, 2023Ryan ScottThe FDA has granted fast track designation to the RNA replacement enzyme–based cancer gene therapy RZ-001 for the treatment of patients with glioblastoma, according to an an
World medicine November 16,2023
FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

November 15, 2023Ryan ScottThe FDA has granted fast track designation to the RNA replacement enzyme–based cancer gene therapy RZ-001 for the treatment of patients with glioblastoma, according to an an
World medicine November 16,2023
Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma

Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma

August 27, 2022Nichole TuckerHigh-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with new
World medicine November 16,2023
Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma

Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma

August 27, 2022Nichole TuckerHigh-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with new
World medicine November 16,2023
Is Telogen Effluvium Reversible?

Is Telogen Effluvium Reversible?

Telogen effluvium is the second most common reason for hair lossByNancy LeBrunPublished on October 19, 2023Medically reviewed bySusan Bard, MDTable of ContentsHow to Know If Yo
World medicine November 16,2023
Is Telogen Effluvium Reversible?

Is Telogen Effluvium Reversible?

Telogen effluvium is the second most common reason for hair lossByNancy LeBrunPublished on October 19, 2023Medically reviewed bySusan Bard, MDTable of ContentsHow to Know If Yo
World medicine November 16,2023
Conditions That Affect Your Scalp and How to Identify Them

Conditions That Affect Your Scalp and How to Identify Them

BySherry ChristiansenUpdated on July 21, 2023Medically reviewed byLindsay Cook, PharmDScalp conditions can be irritating, but do not usually cause any major complications. Most
World medicine November 16,2023
Conditions That Affect Your Scalp and How to Identify Them

Conditions That Affect Your Scalp and How to Identify Them

BySherry ChristiansenUpdated on July 21, 2023Medically reviewed byLindsay Cook, PharmDScalp conditions can be irritating, but do not usually cause any major complications. Most
World medicine November 16,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com